03:25 AM EDT, 08/25/2026 (MT Newswires) -- Solvonis Therapeutics (SVNS.L) raised 1.3 million pounds sterling from the placement of 1,083,333,333 new ordinary shares. The late-stage clinical biopharmaceutical company will also issue 10 million new shares at 0.0015 pound apiece as payment for 15,000 pounds of fees related to the offering, according to a Tuesday filing. The company intends to use net proceeds from the offering primarily for the assessment of potential additional sites for the ongoing SVN-001 phase 3 study, preparation of an investigational new drug application and phase 2b trial in the US for SVN-002, and the advancement of SVN-015 alongside the US National Institute on Drug Abuse. Remaining proceeds are earmarked for general working capital use and other expenses.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.